Key facts
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 May 2024, 21:36.
Robert E. Waltermire - 21 May 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Senior VP, Chief Pharma Dev.
- Issuer ticker
- MDGL
- Reported as of
- 21 May 2024
- Net transaction value
- -$239,668
- SEC form
- 4
- Accepted by SEC
- 23 May 2024, 21:36:56 UTC
- Prior SEC filing
- 25 Jan 2024
- Next SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mardi Dier, as Attorney-in-Fact**
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 23 May 2024.
Change
- Previous filing in this sequence was filed on 25 Jan 2024.
- Current net transaction value: -$239,668.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDGL
transaction
Common Stock
Sale
- Transaction value
- $239,668
- Shares
- -1,036
- Change %
- -16%
- Price
- $231.34
- Shares after
- 5,500
- Date
- 21 May 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24 - Power of Attorney